S&P 500   3,837.75 (+1.84%)
DOW   31,465.24 (+1.75%)
QQQ   308.88 (+1.57%)
AAPL   121.36 (+1.02%)
MSFT   232.79 (+2.67%)
FB   264.09 (+2.50%)
GOOGL   2,092.62 (+2.89%)
TSLA   599.16 (-3.59%)
AMZN   3,002.16 (+0.83%)
NVDA   499.01 (+0.85%)
BABA   234.90 (+1.91%)
CGC   30.98 (-0.10%)
GE   13.52 (-0.37%)
MU   89.13 (+5.69%)
NIO   37.75 (-3.90%)
AMD   78.73 (+1.26%)
T   29.67 (+2.59%)
F   12.25 (+2.68%)
ACB   9.55 (-2.75%)
DIS   190.00 (+1.05%)
BA   222.48 (-0.99%)
NFLX   514.13 (+0.56%)
BAC   36.93 (+1.18%)
S&P 500   3,837.75 (+1.84%)
DOW   31,465.24 (+1.75%)
QQQ   308.88 (+1.57%)
AAPL   121.36 (+1.02%)
MSFT   232.79 (+2.67%)
FB   264.09 (+2.50%)
GOOGL   2,092.62 (+2.89%)
TSLA   599.16 (-3.59%)
AMZN   3,002.16 (+0.83%)
NVDA   499.01 (+0.85%)
BABA   234.90 (+1.91%)
CGC   30.98 (-0.10%)
GE   13.52 (-0.37%)
MU   89.13 (+5.69%)
NIO   37.75 (-3.90%)
AMD   78.73 (+1.26%)
T   29.67 (+2.59%)
F   12.25 (+2.68%)
ACB   9.55 (-2.75%)
DIS   190.00 (+1.05%)
BA   222.48 (-0.99%)
NFLX   514.13 (+0.56%)
BAC   36.93 (+1.18%)
S&P 500   3,837.75 (+1.84%)
DOW   31,465.24 (+1.75%)
QQQ   308.88 (+1.57%)
AAPL   121.36 (+1.02%)
MSFT   232.79 (+2.67%)
FB   264.09 (+2.50%)
GOOGL   2,092.62 (+2.89%)
TSLA   599.16 (-3.59%)
AMZN   3,002.16 (+0.83%)
NVDA   499.01 (+0.85%)
BABA   234.90 (+1.91%)
CGC   30.98 (-0.10%)
GE   13.52 (-0.37%)
MU   89.13 (+5.69%)
NIO   37.75 (-3.90%)
AMD   78.73 (+1.26%)
T   29.67 (+2.59%)
F   12.25 (+2.68%)
ACB   9.55 (-2.75%)
DIS   190.00 (+1.05%)
BA   222.48 (-0.99%)
NFLX   514.13 (+0.56%)
BAC   36.93 (+1.18%)
S&P 500   3,837.75 (+1.84%)
DOW   31,465.24 (+1.75%)
QQQ   308.88 (+1.57%)
AAPL   121.36 (+1.02%)
MSFT   232.79 (+2.67%)
FB   264.09 (+2.50%)
GOOGL   2,092.62 (+2.89%)
TSLA   599.16 (-3.59%)
AMZN   3,002.16 (+0.83%)
NVDA   499.01 (+0.85%)
BABA   234.90 (+1.91%)
CGC   30.98 (-0.10%)
GE   13.52 (-0.37%)
MU   89.13 (+5.69%)
NIO   37.75 (-3.90%)
AMD   78.73 (+1.26%)
T   29.67 (+2.59%)
F   12.25 (+2.68%)
ACB   9.55 (-2.75%)
DIS   190.00 (+1.05%)
BA   222.48 (-0.99%)
NFLX   514.13 (+0.56%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:NTRP

Neurotrope Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.94
0.00 (0.00 %)
(As of 12/2/2020)
Add
Compare
Today's Range
$0.94
Now: $0.94
$0.94
50-Day Range
$0.92
MA: $0.96
$1.05
52-Week Range
$0.68
Now: $0.94
$3.85
VolumeN/A
Average Volume597,206 shs
Market Capitalization$22.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.27
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.
Neurotrope logo

Headlines

Form 8-K Synaptogenix, Inc. For: Dec 15 - StreetInsider.com
December 16, 2020 |  streetinsider.com
Form 8-K Synaptogenix, Inc. For: Dec 06 - StreetInsider.com
December 10, 2020 |  streetinsider.com
Insider Buys Neurotrope Stock - Yahoo Finance
November 2, 2020 |  finance.yahoo.com
Insider Buys Neurotrope's Stock
October 26, 2020 |  finance.yahoo.com
Insider Buys Neurotrope Stock
October 22, 2020 |  finance.yahoo.com
Insider Buys Neurotrope's Stock - Benzinga
October 22, 2020 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRP
CUSIPN/A
Phone973-242-0005
Employees5
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.33 per share

Profitability

Net Income$-15,140,000.00

Miscellaneous

Market Cap$22.39 million
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

0.59 out of 5 stars

Medical Sector

1359th out of 1,969 stocks

Pharmaceutical Preparations Industry

602nd out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

What stocks does MarketBeat like better than Neurotrope?

Wall Street analysts have given Neurotrope a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neurotrope wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Neurotrope's earnings last quarter?

Neurotrope, Inc. (NASDAQ:NTRP) posted its quarterly earnings results on Tuesday, October, 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.05.
View Neurotrope's earnings history
.

Who are Neurotrope's key executives?

Neurotrope's management team includes the following people:
  • Dr. Charles S. Ryan J.D., Ph.D., Chief Exec. Officer and Director (Age 56, Pay $850.21k)
  • Dr. Daniel L. Alkon, Pres & Chief Science Officer (Age 78, Pay $275k)
  • Mr. Robert Weinstein, Chief Financial Officer, Exec. VP, Sec. and Treasurer (Age 60, Pay $423.82k)
  • Mr. Jeffrey Benison, Director of Corp. Communications
  • Dr. Alan J. Tuchman, Acting Chief Medical Officer (Age 73)

Who are some of Neurotrope's key competitors?

What other stocks do shareholders of Neurotrope own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Alibaba Group (BABA), KemPharm (KMPH), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), VistaGen Therapeutics (VTGN), (CGC) and Intel (INTC).

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $0.94.

How much money does Neurotrope make?

Neurotrope has a market capitalization of $22.39 million.

How many employees does Neurotrope have?

Neurotrope employs 5 workers across the globe.

What is Neurotrope's official website?

The official website for Neurotrope is www.neurotropebioscience.com.

Where are Neurotrope's headquarters?

Neurotrope is headquartered at 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036.

How can I contact Neurotrope?

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.